公开(公告)号：US10076491B2

公开(公告)日：2018-09-18

申请号：US14166965

申请日：2014-01-29

Applicant: NITTO DENKO CORPORATION

Inventor： Daisuke Asari ,  Katsuyuki Okubo ,  Takuya Shishido ,  Arimichi Okazaki ,  Yoshiki Maeda ,  Kyohei Matsushita ,  Wenjing Li ,  Mitsuhiko Hori ,  Haruo Sugiyama

IPC: A61K39/00 ,  A61K39/02 ,  A61K45/06 ,  A01N63/00 ,  A61K31/7004 ,  A61K9/00 ,  A61K31/407 ,  A61K31/192 ,  A61K31/405 ,  A61K31/616 ,  A61K31/196 ,  A61K31/415 ,  A61K31/42 ,  A61K31/4035 ,  A61K31/353 ,  A61K31/5575 ,  A61K31/216 ,  A61K31/426 ,  A61K38/10 ,  A61K39/39

CPC classification number: A61K9/0014 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/353 ,  A61K31/4035 ,  A61K31/405 ,  A61K31/407 ,  A61K31/415 ,  A61K31/42 ,  A61K31/426 ,  A61K31/5575 ,  A61K31/616 ,  A61K38/10 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/54 ,  A61K2039/572

Abstract: The invention provides a vaccine composition containing an antigen for inducing cellular immunity, comprising at least one first cellular immunity induction promoter.

公开(公告)号：US09439872B2

公开(公告)日：2016-09-13

申请号：US14813797

申请日：2015-07-30

Applicant: NITTO DENKO CORPORATION

Inventor： Kyohei Matsushita ,  Daisuke Asari ,  Takuya Shishido ,  Mitsuhiko Hori

IPC: A61F13/02 ,  A61K9/70 ,  A23L1/30 ,  A23L1/305 ,  A61K38/00 ,  A61K9/00 ,  A61K47/36 ,  A61K9/20 ,  A61K31/48 ,  A61K31/7052 ,  A61K31/715 ,  A61K31/79 ,  A61K31/137 ,  A61K31/138 ,  A61K31/18 ,  A61K31/422 ,  A61K31/426 ,  A61K31/439 ,  A61K31/46 ,  A61K47/18 ,  A61K47/32 ,  A61K47/38

CPC classification number: A61K9/7007 ,  A23L33/13 ,  A23L33/17 ,  A23L33/175 ,  A23P10/00 ,  A61K9/00 ,  A61K9/0056 ,  A61K9/006 ,  A61K9/2054 ,  A61K9/70 ,  A61K9/7015 ,  A61K31/137 ,  A61K31/138 ,  A61K31/18 ,  A61K31/422 ,  A61K31/426 ,  A61K31/439 ,  A61K31/46 ,  A61K31/48 ,  A61K31/7052 ,  A61K31/715 ,  A61K31/79 ,  A61K38/00 ,  A61K47/10 ,  A61K47/183 ,  A61K47/32 ,  A61K47/36 ,  A61K47/38

Abstract: The present invention aims to provide an oral film-form base and an oral film-form preparation which have a rapid dissolution profile in the mouth and sufficient film strength, give a good tactile impression when handled with fingers and favorable texture and taste in the mouth, and are administrable to those who have limitation in carbohydrate intake. The present invention relates to an oral film-form base including an edible polymer soluble in water and an organic solvent having a solubility parameter of 9.7 or higher, and particles of at least one compound selected from the group consisting of amino acid, dipeptide, and nucleotide, the particles of at least one compound selected from the group consisting of amino acid, dipeptide, and nucleotide being dispersed in the state of particles in the oral film-form base.

Abstract translation: 本发明的目的是提供一种在口中具有快速溶出曲线并具有足够的膜强度的口腔膜形式基质和口腔膜形式制剂，在手指处理时具有良好的触觉，口中具有良好的质地和味道 并且对那些在碳水化合物摄入方面有限制的人群是可以管理的。 本发明涉及包含可溶于水的食用聚合物和溶解度参数为9.7以上的有机溶剂的口腔膜型基质，以及至少一种选自氨基酸，二肽和 核苷酸，选自氨基酸，二肽和核苷酸的至少一种化合物的颗粒以口腔膜形式的基质中的颗粒状态分散。

公开(公告)号：US10688120B2

公开(公告)日：2020-06-23

申请号：US15570851

申请日：2016-04-28

Applicant: NITTO DENKO CORPORATION

Inventor： Kyohei Matsushita ,  Masahiro Fukasaka ,  Takuya Shishido ,  Daisuke Asari ,  Katsuyuki Okubo ,  Mitsuhiko Hori

IPC: A61K31/739 ,  A61K39/39 ,  A61K39/00 ,  A61K39/02 ,  A61K39/35 ,  A61P37/02 ,  A61P37/08 ,  A61P11/02 ,  A61P11/06

Abstract: The present invention provides an allergy vaccine composition that is useful as a prophylactic or therapeutic agent for an allergic disease and can safely and effectively induce immune tolerance. The vaccine composition is to be administered to a human or animal with an allergic disease for the prevention or treatment of the allergic disease. The vaccine composition contains: an immunomodulator which is a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt of the lipopolysaccharide; and at least one allergen.

公开(公告)号：US10471140B2

公开(公告)日：2019-11-12

申请号：US16388266

申请日：2019-04-18

Applicant: NITTO DENKO CORPORATION

Inventor： Takuya Shishido ,  Daisuke Asari ,  Kyohei Matsushita ,  Mitsuhiko Hori

IPC: C07K14/705 ,  C07K16/28 ,  C12Q1/68 ,  A61K39/395 ,  C07H21/02 ,  A61K39/39 ,  A61K39/00

Abstract: The present invention aims to provide a composition for promoting humoral immunity induction and a vaccine pharmaceutical composition that can be universally used for various antigens in inducing humoral immunity to antigens, contain a Th2 reaction promoter, and exerts a high humoral immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition containing an antigen for humoral immunity induction and at least one Th2 reaction promoter.

公开(公告)号：US10391167B2

公开(公告)日：2019-08-27

申请号：US14917077

申请日：2014-10-02

Applicant: NITTO DENKO CORPORATION

Inventor： Masahiro Fukasaka ,  Mitsuhiko Hori ,  Katsuyuki Okubo ,  Daisuke Asari ,  Arimichi Okazaki ,  Eiji Kiyotoh ,  Kyohei Matsushita

IPC: A61K39/00 ,  A61K39/39 ,  A61K39/15 ,  A61K39/09 ,  A61K39/12 ,  A61K39/13 ,  A61K39/145 ,  C12N7/00

Abstract: The present disclosure relates to a method for inducing humoral immunity in a human or animal, that includes administering to the human or animal a mucosal vaccine composition to a mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane. The mucosal vaccine composition includes at least one antigen derived from a pathogen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Pantoea, Acetobacter, Zymomonas, and Xanthomonas, or a salt of the lipopolysaccharide, wherein the mass ratio between a total mass of the adjuvant and a total mass of the antigen is 0.002 to 500. The mucosal vaccine composition is administered in an amount effective to induce humoral immunity in the human or animal.

公开(公告)号：US09962439B2

公开(公告)日：2018-05-08

申请号：US14916807

申请日：2014-10-02

Applicant: NITTO DENKO CORPORATION

Inventor： Kyohei Matsushita ,  Masahiro Fukasaka ,  Arimichi Okazaki ,  Eiji Kiyotoh ,  Katsuyuki Okubo ,  Daisuke Asari ,  Mitsuhiko Hori

IPC: A61K39/00 ,  A61K39/39 ,  A61K9/00

CPC classification number: A61K39/39 ,  A61K9/0019 ,  A61K39/00 ,  A61K2039/55572

Abstract: The present invention aims at providing an injectable vaccine composition that is safe, useful as a prophylactic or therapeutic agent for cancers or infectious diseases, and capable of inducing the systemic immune response safely and effectively. The present invention is an injectable vaccine composition to be administered by injection to a human being or an animal, containing: at least one antigen, and as an adjuvant, a lipopolysaccharide derived from at least one gram negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.

公开(公告)号：US10925936B2

公开(公告)日：2021-02-23

申请号：US15507443

申请日：2015-09-02

Applicant: NITTO DENKO CORPORATION

Inventor： Takuya Shishido ,  Daisuke Asari ,  Mitsuhiko Hori

IPC: A61K39/00 ,  A61K31/047 ,  A61K31/05 ,  A61K31/085 ,  A61K31/355 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/663 ,  A61K31/675 ,  A61K31/685 ,  A61K33/00 ,  A61K31/42 ,  A61K31/192 ,  A61K31/12 ,  A61K9/70 ,  A61K38/00 ,  A61K31/19 ,  A61K31/4375 ,  A61K9/00 ,  A61K45/06 ,  A61K31/415 ,  A61K31/196 ,  A61K9/06 ,  A61K31/09 ,  A61K31/194 ,  A61K31/198 ,  A61K31/216 ,  A61K31/235 ,  A61K31/352 ,  A61K31/353 ,  A61K31/37 ,  A61K31/375 ,  A61K31/405 ,  A61K31/407 ,  A61K31/421 ,  A61K31/4745 ,  A61K31/5415 ,  A61K31/616 ,  A61K31/635 ,  A61K31/7048 ,  A61K33/04 ,  A61K38/10

Abstract: The present invention aims to provide a vaccine pharmaceutical composition universally usable for induction of cellular immunity against various antigens and exerting a high cellular immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing cellular immunity, containing: an antigen; and a first cellular immunity induction promoter that is a bisphosphonate.

公开(公告)号：US10722570B2

公开(公告)日：2020-07-28

申请号：US15777441

申请日：2016-11-28

Applicant: NITTO DENKO CORPORATION

Inventor： Eiji Kiyotoh ,  Mitsuhiko Hori ,  Daisuke Asari ,  Katsuyuki Okubo ,  Takuya Shishido ,  Masahiro Fukasaka ,  Kyohei Matsushita

IPC: A61K39/00 ,  C07K14/00 ,  C12N9/90 ,  A61K38/00 ,  A61K39/108 ,  A61K39/145 ,  A61K47/26 ,  A61K9/19 ,  A61K47/18 ,  A61P31/16

Abstract: The present invention provides a dried influenza vaccine preparation in which the activity of an influenza vaccine can be stably maintained even if the preparation is stored without strict temperature control and which can be stably supplied. The present invention also provides a method for producing the dried influenza vaccine preparation. Provided is a dried influenza vaccine preparation including: an influenza vaccine antigen; a disaccharide; and an amino acid.

公开(公告)号：US10092642B2

公开(公告)日：2018-10-09

申请号：US14917084

申请日：2014-10-02

Applicant: NITTO DENKO CORPORATION

Inventor： Masahiro Fukasaka ,  Mitsuhiko Hori ,  Katsuyuki Okubo ,  Daisuke Asari ,  Arimichi Okazaki ,  Eiji Kiyotoh ,  Kyohei Matsushita

IPC: A61K39/00 ,  A61K39/385 ,  A61K39/12 ,  A61K9/00 ,  A61K39/04 ,  A61K39/09 ,  A61K39/08 ,  A61K39/13 ,  A61K39/145 ,  A61K39/15 ,  A61K39/155 ,  A61K39/165 ,  A61K39/20 ,  A61K39/205 ,  A61K39/25 ,  A61K39/29 ,  C12N7/00

Abstract: The present invention aims at providing a mucosal vaccine composition that can be administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response. The present invention provides a mucosal vaccine composition to be administered to at least one mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, containing: at least one antigen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.

公开(公告)号：US10071155B2

公开(公告)日：2018-09-11

申请号：US14916721

申请日：2014-10-02

Applicant: NITTO DENKO CORPORATION

Inventor： Eiji Kiyotoh ,  Mitsuhiko Hori ,  Katsuyuki Okubo ,  Daisuke Asari ,  Arimichi Okazaki ,  Masahiro Fukasaka ,  Kyohei Matsushita

IPC: A61K39/00 ,  A61K39/39 ,  A61K39/08 ,  A61K39/09 ,  A61K39/12 ,  A61K39/125 ,  A61K39/13 ,  A61K39/145 ,  A61K39/15 ,  A61K39/165 ,  A61K39/205 ,  A61K39/25

CPC classification number: A61K39/39 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/08 ,  A61K39/092 ,  A61K39/12 ,  A61K39/125 ,  A61K39/13 ,  A61K39/145 ,  A61K39/15 ,  A61K39/165 ,  A61K39/205 ,  A61K39/25 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/543 ,  A61K2039/55572 ,  A61K2039/575 ,  C12N2710/16734 ,  C12N2710/20034 ,  C12N2720/12334 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2760/20134 ,  C12N2770/24134 ,  C12N2770/32434 ,  C12N2770/32634 ,  C12N2770/36234

Abstract: The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively. The present invention provides a nasal mucosal vaccine composition to be administered to a human or animal nasal mucous membrane, the nasal mucosal vaccine composition containing at least one antigen excluding antigens derived from influenza viruses; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.